Genentech, Inc.
Clinical trials sponsored by Genentech, Inc., explained in plain language.
-
New hope for ulcerative colitis? drug trial shows promise
Disease control TerminatedThis study tested a drug called vixarelimab in 79 people with moderate to severe ulcerative colitis who did not get better with other treatments. The goal was to see if the drug could help control the disease and reduce symptoms like diarrhea and bleeding. The study was stopped e…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 09, 2026 05:19 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug, RO7759065, alone or with another drug (atezolizumab) in 12 people with advanced solid tumors that could not be cured. The main goal was to check safety and find the right dose. The trial was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Kidney shield drug trial halted early – what it means for heart surgery patients
Prevention TerminatedThis study tested whether the drug GDC-8264 could prevent acute kidney injury and serious kidney problems in people having heart surgery. About 67 participants at moderate to high risk were enrolled, but the trial was stopped early. The goal was to see if the drug worked better t…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Prevention
Last updated May 06, 2026 16:02 UTC